Tepezza lawsuit claims continue to grow across the United States in 2026. Patients treated with Tepezza for thyroid eye disease allege the drug caused permanent hearing damage. These cases target Amgen Inc., which acquired the drug’s original manufacturer, Horizon Therapeutics, in 2023. The litigation centers on allegations that the company failed to adequately warn patients and doctors about serious hearing risks. Hundreds of cases have been consolidated into federal multidistrict litigation in Illinois. If you experienced hearing damage after Tepezza treatment, you may be eligible to seek compensation.
Case Timeline
Last checked: July 10, 2026
What Is the Tepezza Lawsuit About?
| MDL Detail | Current Data |
|---|---|
| MDL Number | MDL-3079 |
| Pending Cases | 277 |
| Presiding Judge | Thomas M. Durkin |
| Federal District | N.D. Ill. |
| Data Source | U.S. Judicial Panel on Multidistrict Litigation |
| Last Updated | July 06, 2026 |
Tepezza (teprotumumab-trbw) is an injectable biologic drug approved by the FDA in January 2020. It treats thyroid eye disease, a condition also known as Graves’ orbitopathy. The disease causes swelling, bulging, and inflammation behind the eyes. Horizon Therapeutics developed and marketed it as the first FDA-approved treatment for this condition. In October 2023, Amgen Inc. completed its acquisition of Horizon. As a result, Amgen now faces legal responsibility for Tepezza-related injury claims.
The core allegation in each Tepezza lawsuit is straightforward. Plaintiffs claim the manufacturer knew about serious hearing risks before and after FDA approval. However, the company marketed the drug without adequate warnings about permanent damage. Clinical trial data showed hearing-related side effects during testing. A study at the 2021 Endocrine Society meeting found that 65% of patients experienced hearing problems. A separate 2022 observational study reported that 81.5% developed new or worsening hearing symptoms.
Injuries alleged in these cases include permanent sensorineural hearing loss, chronic tinnitus, and hyperacusis. Many plaintiffs report significant impacts on their quality of daily life. In most cases, patients received multiple infusions before symptoms appeared. The FDA updated the Tepezza label in July 2023 to include stronger hearing warnings. Plaintiffs argue this label change came years too late for patients already harmed by the drug.
MDL Case Status and Key Facts
| Detail | Information |
|---|---|
| MDL Number | 3079 |
| Full Case Name | In Re: Tepezza (Teprotumumab) Products Liability Litigation |
| Federal District | Northern District of Illinois |
| Presiding Judge | Hon. Thomas M. Durkin |
| Approx. Case Count | ~280 pending (early 2026) |
| Consolidation Date | June 2, 2023 |
| First Bellwether Trial | June 8, 2026 |
| Defendant | Amgen Inc. (formerly Horizon Therapeutics) |
The Judicial Panel on Multidistrict Litigation consolidated these cases in June 2023. Judge Durkin oversees all federal pretrial proceedings in Chicago. The Tepezza lawsuit docket has grown steadily since consolidation. Approximately 280 cases were pending in the MDL as of early 2026. New cases continue to be filed and transferred into the litigation.
A bellwether trial program was established in November 2023. Four representative cases were selected to go to trial first. In late 2025, all bellwether deadlines were temporarily canceled amid settlement discussions. However, trial dates have since been rescheduled. The first bellwether trial is now set for June 8, 2026. Additional trials follow in August, September, and November 2026. These outcomes will likely shape settlement discussions for the entire docket.
Chief Magistrate Judge M. David Weisman has overseen the settlement process. Judge Durkin directed the parties to meet at least once per quarter for negotiations. The bellwether results could determine whether a global resolution is reached or individual trials proceed.
Who Qualifies for the Tepezza Lawsuit?
You may qualify for a Tepezza lawsuit claim if you meet certain criteria. You must have received Tepezza infusions for thyroid eye disease. You must also have developed hearing problems during or after your treatment. Qualifying injuries typically include permanent hearing loss, chronic tinnitus, or both. Symptoms may have appeared during the infusion period or in the months that followed.
The relevant exposure period spans from January 2020 to the present. Tepezza remains on the market with updated safety warnings. However, patients treated before the July 2023 label update have the strongest claims. They received the drug without adequate disclosure of hearing risks. For example, many patients were told that hearing side effects would be temporary and fully reversible.
Evidence needed to support a claim typically includes medical records showing Tepezza infusion dates and dosage. Audiograms documenting hearing changes before and after treatment are also important. In most cases, attorneys will request records from your prescribing endocrinologist and audiologist. A consultation with a licensed attorney can help determine whether your specific situation qualifies for this litigation.
How to File a Tepezza Lawsuit Claim
Filing a Tepezza lawsuit begins with contacting a qualified attorney. Look for a lawyer experienced in pharmaceutical product liability litigation. Many law firms offer free initial case evaluations. Most attorneys handling these cases work on a contingency fee basis. This means you typically pay nothing upfront. The attorney receives a percentage only if you recover compensation.
After retaining an attorney, you will complete a plaintiff fact sheet. This document details your medical history, Tepezza treatment dates, and hearing injuries. Your legal team will gather supporting records and expert medical opinions. The case is then filed and transferred to the MDL in the Northern District of Illinois for coordinated pretrial proceedings.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Statute of limitations deadlines vary by state. Typically, the filing window ranges from two to four years. The clock usually starts when you discovered or should have discovered the injury. Some patients treated in 2020 or 2021 may be approaching their deadlines now. As a result, consulting an attorney promptly is critical. Do not assume you have unlimited time to take legal action.
Settlement Updates and What to Expect
No global Tepezza lawsuit settlement has been announced as of May 2026. However, structured settlement negotiations have been ongoing for over a year. The quarterly meetings ordered by the court suggest both sides remain engaged. No individual settlements have been publicly disclosed either. The cancellation and rescheduling of bellwether dates reflects the fluid nature of these discussions.
The upcoming bellwether trials will play a critical role in shaping outcomes. These test cases help both sides evaluate the strength of evidence and testimony. Bellwether verdicts in pharmaceutical MDLs often accelerate broader settlement talks. If juries award significant damages, the defendant typically faces stronger pressure to negotiate. The June 2026 trial will be closely watched by plaintiffs, defense counsel, and legal analysts.
Potential settlement values in pharmaceutical MDLs vary widely based on individual circumstances. Severity of hearing loss, patient age, and impact on daily life all matter. Medical expenses and lost income are also key factors. Typically, cases involving permanent bilateral hearing loss receive higher valuations. Each Tepezza lawsuit is evaluated on its own facts and merits. The timeline for full resolution could extend well into 2027 or beyond.
State-by-State Considerations
Although the Tepezza lawsuit is consolidated in federal court in Illinois, state laws still affect individual claims. Each state has its own statute of limitations, damage caps, and product liability standards. For example, California and New York have significant plaintiff populations in this MDL. Texas, Florida, and Illinois also have notable case counts.
Some states impose caps on non-economic damages like pain and suffering. Others require specific expert testimony standards for pharmaceutical claims. These differences can substantially affect claim values. You can review the 50-state tort reform comparison for details on your state. Consulting an attorney licensed in your jurisdiction is essential for understanding how local tort reform laws apply.
Frequently Asked Questions
Is there a deadline to file a Tepezza lawsuit?
Yes. Each state imposes its own statute of limitations for product liability claims. Deadlines typically range from two to four years from injury or discovery. Contact a licensed attorney as soon as possible to determine your specific filing deadline before your window closes.
Can I file a claim if I only have mild hearing loss or tinnitus?
You might be eligible even with partial hearing loss or tinnitus alone. Both permanent and temporary hearing damage may be grounds for a claim. The severity of your injury will affect the potential value. An experienced attorney can evaluate your medical records and advise you on next steps.
How long will the Tepezza lawsuit take to resolve?
Pharmaceutical MDLs typically take several years to reach full resolution. Bellwether trials scheduled for mid-to-late 2026 will help shape the overall timeline. Settlement negotiations are also ongoing. As a result, individual case timelines depend on trial outcomes and the progress of any global settlement agreement.
Check If You May Qualify
Mass tort eligibility depends on your specific exposure, injuries, and the state where you live. A licensed mass tort attorney can evaluate your situation at no upfront cost — most work on contingency, meaning you pay nothing unless you recover compensation.
Official Sources & Resources
For verified mass tort and MDL information:
- JPML: jpml.uscourts.gov — official MDL statistics and transfer orders
- DOJ: justice.gov — settlement announcements and press releases
- FDA: fda.gov — drug recalls, warning letters, and safety alerts
- CDC: cdc.gov — health condition data and exposure guidelines
- EPA: epa.gov — environmental contamination data
- Cornell LII: law.cornell.edu — plain-English legal definitions
Content last reviewed May 2026. This is general educational information, not legal advice. If you notice outdated information, please contact us.
Related Guides
- All Active MDL Cases
- More in This Category
- Tort Reform by State — 50-State Comparison
- All 50 State Tort Reform Guides
- Mass Tort Explainers
- Demographic Guides
- Mass Tort Tips
- Florida Tort Reform Guide
- New Jersey Tort Reform Guide
- Georgia Tort Reform Guide
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content. Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.